Determination of the impurity profile of ethyl-2-(4-{(5R)-3-[4-(methoxycarboxamidoiminomethyl)-phenyl]-2-oxo-5-oxazolidinylmethyl}-1-piperazinyl) acetate, citrate, a highly active platelet aggregation inhibitor, by liquid chromatography-mass spectrometry

Journal of Chromatography A

Volumn 854, Issue 1-2, 1999, Pages 13-22

  Thomasberger, Axel ^a   Engel, Friedel ^a   Feige, Klaus ^a  

^a MERCK KGAA   (Germany)

Author keywords

EMD 122 347; Ethyl 2 (4 (5R) 3 4 (methoxycarboxamidoiminomethyl) phenyl 2 oxo 5 oxazolidinylmethyl 1 piperazinyl) acetate; Pharmaceutical analysis; Platelet aggregation inhibitors

Indexed keywords

4 [[3 [4 [IMINO[(METHOXYCARBONYL)AMINO]METHYL]PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL] 1 PIPERAZINEACETIC ACID ETHYL ESTER; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; COST CONTROL; DRUG DETERMINATION; DRUG IMPURITY; MASS SPECTROMETRY; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, LIQUID; MASS SPECTROMETRY; OXAZOLES; PIPERAZINES; PLATELET AGGREGATION INHIBITORS;

EID: 0032784564     PISSN: 00219673     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9673(99)00633-0     Document Type: Conference Paper

References (7)

1. Gante J., Juraszyk H., Raddatz P., Wurziger H., Bernotat-Danielowski S., Melzer G., Rippmann K.F. Peptides 1996. 1996;401-402 Proceedings of the 24th European Peptide Symposium, Edinburgh, 8-13 September.
2. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. N. Engl. J. Med. 326:1992;242-250.
3. Falk E. Am. J. Cardiol. 68:1991;28B-35B.
4. Deutsche Apoth. Z. 138:1998;608-609.
5. Deutsche Apoth. Z. 138:1998;2900-2901.
6. Docket no. 96D-0009, Int. Conference on Harmonisation; Guideline on Impurities in New Drug Products, Department of Health and Human Services, Food and Drug Administration, Washington, Fed. Reg. 62, No. 96, 19 May, 1997.
7. Lehmann W.D. Massenspektrometrie in der Biochemie, Spektrum Akademischer. 1996;Verlag, Berlin.